
|Videos|July 6, 2022
Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer
Author(s)Urology Times staff
“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.
Advertisement
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Simpa Salami, MD, MPH, discusses the development of urinary biomarkers in prostate cancer detection. Salami is an assistant professor of urology at the University of Michigan, Ann Arbor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5
















































